Article
Pharmacology & Pharmacy
Jinling Cui, Shuang Zhao, Hui Chen, Yuhan Fu, Kai Han, Shutao Yin, Chong Zhao, Lihong Fan, Hongbo Hu
Summary: Acquired resistance to EGFR TKI therapy compromises its efficacy in NSCLC. MET activation is a key strategy for cancer cells to acquire a refractory phenotype. The dysregulated amino acid metabolisms, including elevated expression of ASCT2, SLC7A11, and ASNS, contribute to the survival advantage of gefitinib-resistant cells. MSeA effectively suppresses tumor growth and inactivates the MET-TOPK signaling axis in gefitinib-resistant NSCLC.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Hongwei Han, Cong He, Xingyu Chen, Yuelin Luo, Minkai Yang, Zhongling Wen, Jiabao Hu, Faxiang Lin, Mi Han, Tongming Yin, Rongwu Yang, Hongyan Lin, Jinliang Qi, Yonghua Yang
Summary: In this study, novel shikonin N-benzyl matrinic acid ester derivatives were synthesized and evaluated for their inhibitory effects on cancer cell proliferation. The results showed that some of the ester derivatives exhibited better anti-proliferative activity compared to shikonin and matrine, with less cytotoxicity towards non-cancerous cells. Among them, PMMB-302 demonstrated the strongest anti-proliferative activity against A549 cells, causing cell cycle arrest and inducing apoptosis. Furthermore, PMMB-302 negatively regulated telomerase expression, suggesting its potential as a tumor suppressor in lung cancer cells.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2022)
Article
Oncology
Xuelin Yun, Hailong Qin, Bin Du, Yu Peng, Yuling Liu, Bixian Yang
Summary: The aim of this study was to investigate the antiproliferative activity of hirsuteine (HTE) from Uncaria rhynchophylla (UR) on human NSCLC NCI-H1299 cells and explore the underlying mechanisms. HTE significantly suppressed the proliferation of NCI-H1299 cells in a time- and dose-dependent manner, induced cell cycle arrest and apoptosis. This study suggests that HTE may serve as a promising anticancer compound for the treatment of human NSCLC.
Article
Oncology
Miao Li, Yan Rui, Wenjia Peng, Junfeng Hu, Anbang Jiang, Zeyu Yang, Linian Huang
Summary: This study investigated a novel molecular therapeutic target, FIGNL1, for lung cancer and found that its high expression was associated with decreased function and enhanced cell death in lung cancer cells.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Elena G. Varlamova, Egor A. Turovsky
Summary: Recent studies have shown the cytotoxic effect of selenium-containing compounds, particularly methylseleninic acid, on cancer cells. Although it has selective cytotoxic effects and potential for producing anticancer drugs, the specific molecular mechanism remains unclear. Research also focuses on its impact on endoplasmic reticulum stress and selenoprotein expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Si-Liang Wei, Jing-Jing Ye, Li Sun, Lei Hu, Yuan-Yuan Wei, Da-Wei Zhang, Meng-Meng Xu, Guang-He Fei
Summary: This study identified a novel mechanism involving circKIF20B/miR-615-3p/MEF2A signaling axis in the progression of gefitinib resistance in NSCLC. Downregulation of circKIF20B promotes resistance to gefitinib, while upregulation restores sensitivity. Exosomal circKIF20B may serve as a potential therapeutic target and liquid biopsy candidate in gefitinib-resistant NSCLC.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Dana M. Zaher, Wafaa S. Ramadan, Raafat El-Awady, Hany A. Omar, Fatema Hersi, Vunnam Srinivasulu, Ibrahim Y. Hachim, Farah I. Al-Marzooq, Cijo G. Vazhappilly, Salim Merali, Carmen Merali, Nelson C. Soares, Paul Schilf, Saleh M. Ibrahim, Taleb H. Al-Tel
Summary: SIMR1281 displayed a multi-target anticancer effect by dual inhibition of glutathione and thioredoxin reductases, inhibiting cell proliferation and inducing apoptosis by inducing DNA damage, perturbing the cell cycle, and pathway inactivation.
Article
Medicine, Research & Experimental
Zhihua Teng, Jie Yao, Ling Zhu, Lufeng Zhao, Gang Chen
Summary: This study revealed that ZNF655 is abundantly expressed in NSCLC, and its knockdown can inhibit the malignant behaviors of tumor cells, leading to decreased tumorigenesis. ZNF655 may regulate apoptosis of NSCLC cells through the PI3K/Akt and p53 signaling pathways.
Article
Plant Sciences
Gao-Qian Song, Pu Wu, Xue-Man Dong, Long-Hui Cheng, Hua-Qiu Lu, Yuan-Yuan Lin, Wei-Yang Tang, Tian Xie, Jian-Liang Zhou
Summary: This study investigated the mechanism of action of Elemene (EE) and its main active components (BE and BC) against lung adenocarcinoma. Animal experiments showed that EE effectively suppressed tumor growth, while in vitro experiments showed that BE and BC blocked the cell cycle and induced apoptosis in lung adenocarcinoma cells. Non-targeted metabolomics analysis indicated that the glutathione metabolism pathway in A549 cells was altered after treatment with the active components. Scoring: 8/10
JOURNAL OF ETHNOPHARMACOLOGY
(2023)
Article
Cell Biology
Ali Mohammadi, Behzad Mansoori, Pascal H. G. Duijf, Elham Safarzadeh, Leila Tebbi, Souzan Najafi, Behrooz Shokouhi, Grith L. Sorensen, Uffe Holmskov, Behzad Baradaran
Summary: Low miR-330 expression in lung cancer predicts poor prognosis, but stable restoration of miR-330 expression can reduce cell viability, increase apoptotic cells, induce G2/M cell cycle arrest, and inhibit cell migration.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Wenli Hu, Yurong Ma, Chong Zhao, Shutao Yin, Hongbo Hu
Summary: This study demonstrated that MSeA can effectively attenuate cisplatin-induced PD-L1 expression, enhance its cytotoxicity, and improve tumor sensitivity to chemotherapy drugs. Additionally, MSeA also inhibits IFN-gamma-induced tumor PD-L1 expression, enhances T-cell immunity, and improves the efficacy of chemotherapy drugs.
MOLECULAR CARCINOGENESIS
(2021)
Article
Biochemistry & Molecular Biology
Eul-Bee Ko, Yin-Gi Jang, Cho-Won Kim, Ryeo-Eun Go, Hong Kyu Lee, Kyung-Chul Choi
Summary: This study demonstrates the anti-cancer potential of gallic acid in lung cancer by regulating the PI3K/Akt pathway. Various experimental methods were used to confirm this, including cell assays and mouse models. The results showed that gallic acid inhibits lung cancer progression by inducing cell cycle arrest and apoptosis.
BIOMOLECULES & THERAPEUTICS
(2022)
Article
Oncology
Haini Wang, Junli Zuo
Summary: Overexpressed survivin is associated with worse survival of several types of human tumors. In this study, the antitumor activity of shikonin in non-small-cell lung cancer (NSCLC) by regulating survivin pathway was investigated. Result showed that shikonin inhibited the NSCLC H1299 cell proliferation in a dose-dependent manner. Moreover, shikonin fits well with survivin by molecular docking. Shikonin also inhibited the mRNA expression and protein level of survivin in H1299 cells. Shikonin arrested H1299 cell cycle at the G0/G1 phase by regulating CDK/cyclin family members. In addition, shikonin regulated the expression of X-linked inhibitor of apoptosis- (XIAP-) mediated caspases 3 and 9, thus leading to the damage of mitochondrial membrane potential and induction of H1299 cell apoptosis. Overall, shikonin inhibited H1299 cell growth by inducing apoptosis and blocking the cell cycle. The underlying mechanism involves targeting survivin, which subsequently regulates the protein expression of XIAP/caspase 3/9, CDK2/4, and cyclin E/D1. Thus, shikonin, a survivin inhibitor, is a promising therapeutic strategy in NSCLC treatment.
ANALYTICAL CELLULAR PATHOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jeyce Kelle Ferreira de Andrade, Alexandre Jose da Silva Goes, Vanessa Xavier Barbosa, Mariza Severina de Lima Silva, Mariana Aragao Matos Donato, Christina Alves Peixoto, Gardenia Carmen Gadelha Militao, Teresinha Goncalves da Silva
Summary: Thiosemicarbazones derived from beta-lapachone showed potent cytotoxic effects on leukemia cells, with BV3 being the most selective compound, exhibiting high toxicity to tumor cells and low toxicity to normal cells. These compounds have the potential to be promising candidates for anticancer drugs.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Article
Oncology
Jakeb S. S. M. Petersen, Sarah K. Baird
Summary: The study compared the efficacy of anthelmintic drugs mebendazole and albendazole in breast and colon cancer cell lines, revealing their selective cancer cell killing ability through classical apoptosis and cell cycle arrest involving microtubule destabilization.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Chengfei Liu, Wei Lou, Yezi Zhu, Joy C. Yang, Nagalakshmi Nadiminty, Nilesh W. Gaikwad, Christopher P. Evans, Allen C. Gao
Article
Oncology
Yezi Zhu, Chengfei Liu, Cameron Armstrong, Wei Lou, Amandeep Sandher, Allen C. Gao
CLINICAL CANCER RESEARCH
(2015)
Article
Endocrinology & Metabolism
Chengfei Liu, Wei Lou, Cameron Armstrong, Yezi Zhu, Christopher P. Evans, Allen C. Gao
Article
Oncology
Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan Lombard, Christopher P. Evans, Allen C. Gao
MOLECULAR CANCER THERAPEUTICS
(2017)
Article
Oncology
Chengfei Liu, Cameron Armstrong, Yezi Zhu, Wei Lou, Allen C. Gao
Article
Oncology
Yuanyuan Cui, Nagalakshmi Nadiminty, Chengfei Liu, Wei Lou, Chad T. Schwartz, Allen C. Gao
ENDOCRINE-RELATED CANCER
(2014)
Article
Oncology
Sifeng Qu, Kendric Wang, Hui Xue, Yuwei Wang, Rebecca Wu, Chengfei Liu, Allen C. Gao, Peter W. Gout, Colin C. Collins, Yuzhuo Wang
MOLECULAR ONCOLOGY
(2014)
Article
Endocrinology & Metabolism
Chengfei Liu, Yezi Zhu, Wei Lou, Yuanyuan Cui, Christopher P. Evans, Allen C. Gao
Article
Endocrinology & Metabolism
Yezi Zhu, Chengfei Liu, Yuanyuan Cui, Nagalakshmi Nadiminty, Wei Lou, Allen C. Gao
Article
Multidisciplinary Sciences
Chengfei Liu, Wei Lou, Joy C. Yang, Liangren Liu, Cameron M. Armstrong, Alan P. Lombard, Ruining Zhao, Onika D. V. Noel, Clifford G. Tepper, Hong-Wu Chen, Marc Dall'Era, Christopher P. Evans, Allen C. Gao
NATURE COMMUNICATIONS
(2018)
Article
Oncology
Chengfei Liu, Joy C. Yang, Cameron M. Armstrong, Wei Lou, Liangren Liu, Xiaomin Qiu, Binhao Zou, Alan P. Lombard, Leandro S. D'Abronzo, Christopher P. Evans, Allen C. Gao
MOLECULAR CANCER THERAPEUTICS
(2019)
Article
Oncology
Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Summary: Next-generation antiandrogen drugs improve survival and quality of life in advanced prostate cancer patients, but resistance to these drugs is not well understood. This study found that the Wnt5a/FZD2 signaling pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway could be a potential therapy for advanced prostate cancer.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Oncology
Pengfei Xu, Joy C. Yang, Bo Chen, Christopher Nip, Jonathan E. Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P. Evans, William J. Murphy, Chengfei Liu
Summary: This study investigated the mechanisms underlying the failure of atezolizumab and enzalutamide combination treatment in castration-resistant prostate cancer. The researchers found that enzalutamide-resistant prostate cancer cells promote immunosuppressive signaling, which may contribute to the reduced efficacy of immune checkpoint inhibitors in these patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P. Lombard, Chengfei Liu, Allen C. Gao
Summary: Treatment resistance is a common challenge in castration-resistant prostate cancer. This study examines the resistance patterns of different therapeutic classes and emphasizes the importance of rational drug sequencing in treatment. The findings reveal distinct cross-resistance characteristics among different resistant cell sublines and provide insights into the underlying mechanisms of resistance.
Meeting Abstract
Oncology
Joy C. Yang, Shu Ning, Hans Adomat, Martin Gleave, Allen Gao, Christopher P. Evans, Chengfei Liu